• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/16/21 4:46:31 PM ET
    $ARYA
    Business Services
    Finance
    Get the next $ARYA alert in real time by email
    SC 13G 1 brhc10020420_sc13g.htm SC 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
     

    SCHEDULE 13G
     
    UNDER THE SECURITIES EXCHANGE ACT OF 1934



    ARYA Sciences Acquisition Corp III
    (Name of Issuer)
     
    CLASS A ORDINARY SHARES, $0.0001 PAR VALUE PER SHARE
     
    (Title of Class of Securities)
     
    G3166W 106
     
    (CUSIP Number)
     
    December 31, 2020
    (Date of Event Which Requires Filing of this Statement)



    Check the Appropriate Box to Designate the Rule Pursuant to Which this Schedule Is Filed:
     
    ☐
    Rule 13d-1(b)
     
    ☐
    Rule13d-1(c)
     
    ☒
    Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
     
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


    1
    NAMES OF REPORTING PERSONS
     
     
    ARYA Sciences Holdings III
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Cayman Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    4,146,500(1)
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    4,146,500(1)
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    4,146,500(1)
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    21.6%(1)(2)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     

    2


    1
    NAMES OF REPORTING PERSONS
     
     
    Adam Stone
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    4,146,500(1)
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    4,146,500(1)
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    4,146,500(1)
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    21.6%(1)(2)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     

    3

    1
    NAMES OF REPORTING PERSONS
     
     
    Michael Altman
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    4,146,500(1)
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    4,146,500(1)
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    4,146,500(1)
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    21.6%(1)(2)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     


    (1)
    See Item 4. Represents: (i) 3,647,500 Class B ordinary shares, $0.0001 par value per share, of the Issuer (the “Class B ordinary shares”) directly held by ARYA Sciences Holdings III (the “Sponsor”) and which will automatically convert into the Class A ordinary shares, $0.0001 par value per share, of the Issuer (the “Class A ordinary shares”) at the time of the Issuer’s initial business combination and as more fully described under the heading “Description of Securities—Founder Shares” in the Issuer’s Prospectus filed with the Securities and Exchange Commission (the “SEC”) pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended, on August 10, 2020 (File Nos. 333-239986 and 333-241828) (the “IPO Prospectus”) or the Issuer’s amended and restated memorandum and articles of association; and (ii) 499,000 Class A ordinary shares issued to the Sponsor in a private placement in connection with the Issuer’s initial public offering (the “private placement shares”) and which are identical to the Issuer’s Class A ordinary shares, subject to certain limited exceptions as more fully described under the heading “Description of Securities—Private Placement Shares” in the IPO Prospectus.
     

    (2)
    Based on 14,950,000 Class A ordinary shares, 499,000 private placement shares, and 3,737,500 Class B ordinary shares, issued and outstanding as of November 13, 2020 as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on November 13, 2020 and assuming the conversion of all Class B ordinary shares into Class A ordinary shares.
     
    4

    Item 1(a)
    Name of Issuer
     
    ARYA Sciences Acquisition Corp III (the “Issuer”)

    Item 1(b)
    Address of the Issuer’s Principal Executive Offices
     
    51 Astor Place, 10th Floor
    New York, NY 10003

    Item 2(a)
    Names of Persons Filing
     
    This Schedule 13G is filed by the entities and persons listed below, all of whom together are referred to herein as the “Reporting Persons”:
     

    a)
    ARYA Sciences Holdings III (the “Sponsor”);
     

    b)
    Adam Stone; and
     

    c)
    Michael Altman.
     
    Item 2(b)
    Address of the Principal Business Office, or if none, Residence
     
    The principal business office of each of the Reporting Persons is:
    51 Astor Place, 10th Floor
    New York, NY 10003

    Item 2(c)
    Citizenship
     
    See responses to Item 4 on each of the cover pages of this Schedule 13G.
     
    Item 2(d)
    Title of Class of Securities
     
    Class A ordinary shares, $0.0001 par value per share.
     
    Item 2(e)
    CUSIP Number
     
    G3166W 106
     
    Item 3.
    If this statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c), check whether the person filing is:
     
    ☐
    (b)  a bank as defined in Section 3(a)(6) or the Exchange Act.
    ☐
    (c)  an insurance company as defined in Section 3(a)(19) of the Exchange Act.
    ☐
    (d)  an investment company registered under Section 8 of the Investment Company Act.
    ☐
    (e)  an investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
    ☐
    (f)  an employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
    ☐
    (g)  a parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
    ☐
    (h)  a savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
    ☐
    (i)  a church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
    ☐
    (j)  a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J).
    ☐
    (k)  a group in accordance with Rule 13d-1(b)(1)(ii)(K).
    ☒
    Not applicable

    5

    Item 4.
    Ownership

    The responses to Items 5 to 11 of each of the cover page of this Schedule 13G are incorporated herein by reference.
     
    As of December 31, 2020, the Reporting Persons hold 3,647,500 Class B ordinary shares and 499,000 private placement shares, representing 21.6% of the Issuer’s issued and outstanding ordinary shares and assuming the conversion of all Class B ordinary shares into Class A ordinary shares.
     
    The Class B ordinary shares will automatically convert into Class A ordinary shares at the time of the Issuer’s initial business combination or earlier at the option of the holders thereof at a one-for-one basis, subject to adjustment, as more fully described in the Issuer’s amended and restated memorandum and articles of association or under the heading “Description of Securities—Founder Shares” in the IPO Prospectus. The private placement shares are identical to the Class A ordinary shares, subject to certain limited exceptions as more fully described under the heading “Description of Securities—Private Placement Shares” in the IPO Prospectus.
     
    The Sponsor is the record holder of the securities reported herein. The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman. As such, Messrs. Stone and Altman have voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the Class B ordinary shares held directly by the Sponsor.
     
    Item 5.
    Ownership of Five Percent or Less of a Class
     
    Not Applicable

    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person
     
    Not Applicable
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
     
    Not Applicable
     
    Item 8.
    Identification and Classification of Members of the Group
     
    Not Applicable
     
    Item 9.
    Notice of Dissolution of Group
     
    Not Applicable
     
    Item 10.
    Certification
     
    Not Applicable

    6

    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    DATE: February 16, 2021
    Arya Sciences Holdings III
       
     
    By:
    /s/ Samuel Cohn
     
    Name:
    Samuel Cohn
     
    Title:
    Secretary

     
    /s/ Adam Stone
     
    Adam Stone

     
    /s/ Michael Altman
     
    Michael Altman

    Exhibit Index
     
    Exhibit No.
    Description
    Exhibit 99.1
    Joint Filing Agreement, dated as of February 16, 2021, by and among ARYA Sciences Holdings III, Adam Stone and Michael Altman.

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations
    (See 18 U.S.C. 1001)


    7

    Get the next $ARYA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARYA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ARYA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MarketBeat Ranks Stocks with Most Insider Buying in June 2021

      SIOUX FALLS, S.D., July 8, 2021 /PRNewswire-PRWeb/ -- MarketBeat, a leading source for stock market data and research tools, has published a monthly list ranking The 10 Stocks with the Most Insider Buying in June 2021. An insider trade occurs when a company executive or individual who has non-public information about a company buys or sells shares of that company's stock. The level of stock that insiders are buying is a potential indicator of the stock's future performance. The MarketBeat editorial team compiled the 10 stocks with the most insider trading by utilizing the company's Stocks with the Most Insider Buying Report. For stocks with the most insider buying, software companies and s

      7/8/21 7:00:00 PM ET
      $UHAL
      $FAII
      $HEC
      $ARYA
      Rental/Leasing Companies
      Consumer Discretionary
      Business Services
      Finance
    • Nautilus Biotechnology Debuts as Publicly Traded Company, Seeks to Deliver on the Untapped Potential of the Human Proteome

      Business combination transaction with Arya Sciences Acquisition Corp III, a special purpose acquisition company sponsored by Perceptive Advisors, closed on June 9, 2021Publicly traded company renamed Nautilus Biotechnology, Inc.Common stock commences trading under ticker symbol “NAUT” on the Nasdaq Global Select Market on June 10, 2021Gross proceeds from this transaction to Nautilus totaled approximately $345 million, combining approximately $145 million of funds held in Arya III’s trust account and a concurrent PIPE financing of $200 million SEATTLE and NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis pla

      6/9/21 10:05:00 PM ET
      $ARYA
      Business Services
      Finance
    • ARYA Sciences Acquisition Corp III Announces Extraordinary General Meeting Teleconference Details

      NEW YORK, June 01, 2021 (GLOBE NEWSWIRE) -- ARYA Sciences Acquisition Corp III ("ARYA") (NASDAQ:ARYA), today announced that, due to the public health and safety concerns related to the coronavirus (COVID-19) pandemic and recommendations and orders from federal and New York authorities, ARYA is strongly encouraging that shareholders attend the extraordinary general meeting of its shareholders on June 8, 2021 at 9:00 a.m., New York City Time (the "General Meeting") remotely by teleconference rather than in person. The purpose of the General Meeting is to vote on certain proposals relating to the previously announced Business Combination Agreement, dated as of February 7, 2021 (the "Business

      6/1/21 5:01:46 PM ET
      $ARYA
      Business Services
      Finance

    $ARYA
    SEC Filings

    See more
    • SEC Form D filed by ARYA Sciences Acquisition Corp III

      D - Nautilus Biotechnology, Inc. (0001808805) (Filer)

      6/22/21 4:58:45 PM ET
      $ARYA
      Business Services
      Finance
    • ARYA Sciences Acquisition Corp III filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Changes in Registrant’s Certifying Accountant, Financial Statements and Exhibits, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Amendments to the Registrant’s Code of Ethics, or Waiver of a Provision of the Code of Ethics, Change in Shell Company Status, Regulation FD Discl

      8-K - Nautilus Biotechnology, Inc. (0001808805) (Filer)

      6/9/21 8:55:39 PM ET
      $ARYA
      Business Services
      Finance
    • SEC Form 425 filed by ARYA Sciences Acquisition Corp III

      425 - ARYA Sciences Acquisition Corp III (0001808805) (Subject)

      6/8/21 5:13:44 PM ET
      $ARYA
      Business Services
      Finance

    $ARYA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by ARYA Sciences Acquisition Corp III

      SC 13D - Nautilus Biotechnology, Inc. (0001808805) (Subject)

      6/30/21 2:26:38 PM ET
      $ARYA
      Business Services
      Finance
    • SEC Form SC 13D filed by ARYA Sciences Acquisition Corp III

      SC 13D - Nautilus Biotechnology, Inc. (0001808805) (Subject)

      6/21/21 5:00:58 PM ET
      $ARYA
      Business Services
      Finance
    • SEC Form SC 13D filed by ARYA Sciences Acquisition Corp III

      SC 13D - Nautilus Biotechnology, Inc. (0001808805) (Subject)

      6/16/21 5:10:03 PM ET
      $ARYA
      Business Services
      Finance

    $ARYA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: PERCEPTIVE ADVISORS LLC bought $55,070,983 worth of Common Stock (5,507,063 units at $10.00), increasing direct ownership by 1% to 497,038 units

      4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

      6/11/21 5:45:24 PM ET
      $ARYA
      Business Services
      Finance
    • SEC Form 4: ALTMAN MICHAEL SETH converted 4,146,500 units into Common Stock

      4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

      6/11/21 5:32:39 PM ET
      $ARYA
      Business Services
      Finance
    • SEC Form 3 filed by Epperly Melissa B,

      3 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

      6/9/21 9:41:46 PM ET
      $ARYA
      Business Services
      Finance